范圆圆,章 燕,丁 丽

AL型心肌淀粉样变以严重心力衰竭为首发表现，临床特征为心室肥厚伴心电图低电压、贫血及球蛋白升高，病情进展迅速、预后极差，早期识别并转诊血液科治疗是改善预后的关键。

免疫球蛋白轻链淀粉样变；心肌淀粉样变；心力衰竭；多发性骨髓瘤

[1] Garcia-Pavia P,Rapezzi C,Adler Y,et al.Diagnosis and treatment of cardiac amyloidosis:a position statement of the ESC Working Group on Myocardial and Pericardial Diseases[J].Eur Heart J,2021,42(16):1554-1568. [2] Kumar N,Zhang NJ,Cherepanov D,et al.Global epidemiology of amyloid light-chain amyloidosis[J].Orphanet J Rare Dis,2022,17(1):278. [3] Hester LL,Gifkins DM,Bellew KM,et al.Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523US adults diagnosed between 2001 and 2019[J].Eur J Haematol,2021,107(4):428-435. [4] Buxbaum JN,Dispenzieri A,Eisenberg DS,et al.Amyloid nomenclature 2022:update,novel proteins,and recommendations by the International Society of Amyloidosis(ISA)Nomenclature Committee[J].Amyloid,2022,29(4):213-219. [5] D’ERRICO S,MAZZANTI A,BALDARI B,et al.Sudden death in lambda light chain AL cardiac amyloidosis:a reviewof literature and update for clinicians and pathologists[J].Int J Clin Exp Pathol,2020,13(7):1474-1482. [6] Agis H,Krauth MT.Immunoglobulin light chain amyloidosis:short tutorial in screening,early detection,risk assessment and response evaluation[J].memo-Mag Eur Med Oncol,2021,14(1):103-110. [7] Melero Polo J,Roteta Unceta-Barrenechea A,Revilla MartíP,et al.Echocardiographic markers of cardiac amyloidosis in patients with heart failure and left ventricular hypertrophy[J].Cardiol J,2023,30(2):266-275. [8] Dorbala S,Ando Y,Bokhari S,et al.ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis:Part 2 of 2-Diagnostic Criteria and Appropriate Utilization[J].Circ Cardiovasc Imaging, 2021,14(7):e000030. [9] Maritan M,Romeo M,Oberti L,et al.Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains[J].J Mol Biol,2020,432(4):845-860. [10] Palladini G,Milani P,Merlini G.Predicting survival in light chain amyloidosis[J].Haematologica,2019,104(7):1294-1296. [11] Kumar S,Dispenzieri A,Lacy MQ,et al.Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements[J].J Clin Oncol,2012,30(9):989-995. [12] Vaxman I,Kumar SK,Buadi F,et al.Correction:Outcomes among newly diagnosed AL amyloidosis patients with a very high NT- proBNP:implications for trial design[J].Leukemia,2024,38(8):1866. [13] Gustine JN,Staron A,Mendelson L,et al.Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis[J].Blood Adv,2023,7(20):6080-6091. [14] Gertz MA.Immunoglobulin light chain amyloidosis:2024 update on diagnosis,prognosis,and treatment[J].Am J Hematol,2024,99(2):309-324. [15] Dispenzieri A.Treatment and prognosis of immunoglobulin light chain(AL)amyloidosis and light and heavy chain deposition diseases [M].Wolters Kluwer,2022.

点击下载PDF